Last reviewed · How we verify

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

NCT03712956 PHASE2 UNKNOWN

A single-center, phase II, single-arm, feasibility study to evaluate PLD (Caelyx®) as an adjuvant chemotherapy regimen in patients with early-stage luminal B breast cancer. The primary endpoint will be to evaluate the feasibility of adjuvant PLD (Caelyx®) for each individual subject. The regimen will be considered feasible if that subject is able to achieve relative dose intensity (RDI) of at least 85% of the 8 cycles of treatment. Caelyx® should be administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.

Details

Lead sponsorEuropean Institute of Oncology
PhasePHASE2
StatusUNKNOWN
Enrolment63
Start dateFri Mar 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
CompletionSun Dec 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Interventions

Countries

Italy